DR not main cause of blindness in diabetics

Article

Diabetic retinopathy (DR) is not the leading cause of ocular co-morbidity in diabetic subjects, according to a study published in the June 2008 issue of the British Journal of Ophthalmology.

Diabetic retinopathy (DR) is not the leading cause of ocular co-morbidity in diabetic subjects, according to a study published in the June 2008 issue of the British Journal of Ophthalmology.

Peter H. Scanlon, MBBS, MD, FRCP, DCH, DRCOG, DO, MRCOphth of Cheltenham General Hospital and colleagues conducted slip-lamp biomicroscopy examinations on diabetic subjects (n=1549) following assessment of best corrected visual acuity (BCVA) by a standardized logarithm of minimum angle resolution (logMAR).

The researchers found subnormal vision (logMAR ≥0.3) in 9.0% of subjects; blindness (logMAR ≥1.3), in 0.45%. For any given eye, sensitivity of subnormal vision was 33.4%, specificity was 85.9%, positive status was 18.6% and negative status was 93.0% predictive of DR. Lenticular opacity, macular degeneration, diabetic maculopathy, other media causes including corneal opacity, and amblyopia were found to be contributory causes of moderate visual loss (logMAR 0.50–0.98) or acuity blindness (logMAR ≥1.0) in 49%, 29%, 15%, 13% and 10% of subjects, respectively.

The researchers concluded that BCVA in isolation is not a reliable indicator of DR, and that DR is not the primary cause of vision loss in diabetic subjects.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.